Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Cited In for PubMed (Select 17434401)

1.

Integrase Strand Transfer Inhibitors in HIV Therapy.

Mesplède T, Wainberg MA.

Infect Dis Ther. 2013 Dec;2(2):83-93. doi: 10.1007/s40121-013-0020-8. Epub 2013 Nov 19.

2.

The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.

Kulkarni R, Hluhanich R, McColl DM, Miller MD, White KL.

Antimicrob Agents Chemother. 2014 Oct;58(10):6145-50. doi: 10.1128/AAC.03591-14. Epub 2014 Aug 4.

3.

A mutation in the DNA polymerase accessory factor of herpes simplex virus 1 restores viral DNA replication in the presence of raltegravir.

Zhou B, Yang K, Wills E, Tang L, Baines JD.

J Virol. 2014 Oct;88(19):11121-9. doi: 10.1128/JVI.01540-14. Epub 2014 Jul 9.

4.

AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies.

Luz PM, Bruyand M, Ribeiro S, Bonnet F, Moreira RI, Hessamfar M, Campos DP, Greib C, Cazanave C, Veloso VG, Dabis F, Grinsztejn B, Chêne G; IPEC/FIOCRUZ Cohort and the Aquitaine ANRS C03 Study Group.

BMC Infect Dis. 2014 May 21;14:278. doi: 10.1186/1471-2334-14-278.

5.

Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.

Costi R, Métifiot M, Chung S, Cuzzucoli Crucitti G, Maddali K, Pescatori L, Messore A, Madia VN, Pupo G, Scipione L, Tortorella S, Di Leva FS, Cosconati S, Marinelli L, Novellino E, Le Grice SF, Corona A, Pommier Y, Marchand C, Di Santo R.

J Med Chem. 2014 Apr 24;57(8):3223-34. doi: 10.1021/jm5001503. Epub 2014 Apr 11.

6.

Long-term efficacy and safety of raltegravir in the management of HIV infection.

Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC.

Infect Drug Resist. 2014 Mar 18;7:73-84. doi: 10.2147/IDR.S40168. eCollection 2014. Review.

7.

The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.

Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA.

AIDS. 2014 Jan 28;28(3):365-76. doi: 10.1097/QAD.0000000000000093.

8.

Recent developments in hiv treatment and their dissemination in poor countries.

Ebrahim O, Mazanderani AH.

Infect Dis Rep. 2013 Jun 6;5(Suppl 1):e2. doi: 10.4081/idr.2013.s1.e2. eCollection 2013 Jun 6. Review.

9.

Molecular features related to HIV integrase inhibition obtained from structure- and ligand-based approaches.

de Carvalho LL, Maltarollo VG, de Lima EF, Weber KC, Honorio KM, da Silva AB.

PLoS One. 2014 Jan 8;9(1):e81301. doi: 10.1371/journal.pone.0081301. eCollection 2014.

10.

Routine HIV screening in Portugal: clinical impact and cost-effectiveness.

Yazdanpanah Y, Perelman J, DiLorenzo MA, Alves J, Barros H, Mateus C, Pereira J, Mansinho K, Robine M, Park JE, Ross EL, Losina E, Walensky RP, Noubary F, Freedberg KA, Paltiel AD.

PLoS One. 2013 Dec 18;8(12):e84173. doi: 10.1371/journal.pone.0084173. eCollection 2013.

11.

Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Rizk ML, Houle R, Chan GH, Hafey M, Rhee EG, Chu X.

Antimicrob Agents Chemother. 2014;58(3):1294-301. doi: 10.1128/AAC.02049-13. Epub 2013 Dec 2.

12.

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.

Wainberg MA.

Scientifica (Cairo). 2012;2012:238278. doi: 10.6064/2012/238278. Epub 2012 Dec 31. Review.

13.

Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.

Bayoumi AM, Barnett PG, Joyce VR, Griffin SC, Sun H, Bansback NJ, Holodniy M, Sanders G, Brown ST, Kyriakides TC, Angus B, Cameron DW, Anis AH, Sculpher M, Owens DK.

J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):382-91. doi: 10.1097/QAI.0000000000000002.

14.

Inhibiting the HIV integration process: past, present, and the future.

Di Santo R.

J Med Chem. 2014 Feb 13;57(3):539-66. doi: 10.1021/jm400674a. Epub 2013 Sep 25. Erratum in: J Med Chem. 2014 Jul 24;57(14):6273.

15.

Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.

Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, Jennings S, Cohen MS, Kashuba AD.

AIDS. 2013 Jun 1;27(9):1413-9. doi: 10.1097/QAD.0b013e32835f2b49.

16.
17.

Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection.

Chen L, Ao Z, Jayappa KD, Kobinger G, Liu S, Wu G, Wainberg MA, Yao X.

Antimicrob Agents Chemother. 2013 Aug;57(8):3547-54. doi: 10.1128/AAC.00100-13. Epub 2013 May 13.

18.

Potential benefit of dolutegravir once daily: efficacy and safety.

Fantauzzi A, Turriziani O, Mezzaroma I.

HIV AIDS (Auckl). 2013;5:29-40. doi: 10.2147/HIV.S27765. Epub 2013 Feb 7.

19.

Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis.

Messiaen P, Wensing AM, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L.

PLoS One. 2013;8(1):e52562. doi: 10.1371/journal.pone.0052562. Epub 2013 Jan 9. Review.

20.

Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.

Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR.

Ann Intern Med. 2013 Jan 15;158(2):84-92. doi: 10.7326/0003-4819-158-2-201301150-00002.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk